Actively Recruiting
Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome
Led by Sobet AG · Updated on 2026-04-23
126
Participants Needed
6
Research Sites
209 weeks
Total Duration
On this page
Sponsors
S
Sobet AG
Lead Sponsor
K
Klinikum Klagenfurt am Wörthersee
Collaborating Sponsor
AI-Summary
What this Trial Is About
Sonodyn is an investigational device that within this clinical investigation is intended for use in patients suffering from low back pain, tension headache or neck pain, originating from therapy-resistant myofascial pain syndrome. Myofascial pain syndrome is a prevalent pain condition in the adult population and a common cause of pain and dysfunction in the musculoskeletal system. It is a trigger point-induced regional musculoskeletal pain disorder affecting one or more muscles or groups of muscles. Sonodyn is a handheld medical device that combines low-energy ultrasound, electrical and magnetic field stimulation for non-invasive transcutaneous treatment of chronic myofascial pain syndrome. Sonodyn is a battery-operated, rechargeable stimulation device to be placed over specific trigger points for associated pain patterns in the human body. It emits ultrasound, electrical and magnetic stimulation signals with a pre-defined set of parameters for each of the independently operated power sources. The study will follow a prospective, randomized, sham-controlled, double-blind parallel group design. It will be conducted as a multi-center investigation at 6 sites in Austria and Switzerland. Patients are randomized in a 2:1 ratio into Treatment and Control. * Active Sonodyn therapy (Treatment) * No therapy (Sham Control) Two types of Sonodyn devices will be used: a fully functional one for Therapy arm patients that can deliver stimulation, and a non-functional one for Control arm patients that cannot convey any energy signals to the device output. The devices will look fully identical. Randomization will be stratified by study site, pain diagnosis and sex of the patient. For each subject, after a screening phase of 1 week, patients will be treated for 3 weeks with a follow-up of additional 8 weeks, adding up to 12 weeks. During treatment patients will activate their device 3 times a day for 10 minutes each. During screening, treatment and follow-up period, all patients will twice per day report the average and maximum intensity of their pain Numeric Rating Scale (NRS). Patients will also enter the date, amount, and time of intake of rescue medication, if applicable. The primary objective of this study is to assess the impact on pain. Secondary objectives are to compare the performance between active therapy and sham, as well as to correlate changes in pain intensity with other pain related scales.
CONDITIONS
Official Title
Low-Energy Ultrasound, Electrical and Magnetic Field Stimulation in Therapy-Resistant Myofascial Pain Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female aged 18 to 99 years at screening
- Patient understands the study and agrees to participate with written informed consent
- Patient has chronic low back pain, tension headache, or neck pain caused mainly by myofascial pain syndrome lasting at least 3 months
- Patient has stable pain treatment for at least 1 week during screening
- Patient has a daily average Numeric Rating Scale (NRS) pain score of 4 or higher on at least 4 of 7 days during screening
- Patient complies with daily pain status reporting requirements
You will not qualify if you...
- Presence of active implants
- Allergy to rescue medication used in the study
- Pregnancy
- Mental or physical impairments that increase risk in using the device
- Epilepsy or cerebral spasms
- Psychiatric diseases or somatoform pain disorders
- Use of oral morphine equivalent exceeding 120mg daily
- Use of centrally acting muscle relaxants such as Sirdalud or benzodiazepines
- Contraindication against NSAIDs
- Artificial joints made from methylmethacrylate or polyethylene at stimulation site
- Ferromagnetic metal implants at stimulation site, including aneurysm clips or dental implants
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
Schmerzambulanz, Krankenhaus der Elisabethinen Graz
Graz, Austria, 8020
Actively Recruiting
2
Abteilung für Anästhesiologie und Intensivmedizin, Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria, 9020
Actively Recruiting
3
Krankenhaus St. Vinzenz Zams
Zams, Austria, 6511
Actively Recruiting
4
RSB Neurochirurgie AG, Salem-Spital Bern
Bern, Switzerland, 3013
Actively Recruiting
5
Clinique de la Douleur, La Tour Hospital
Meyrin, Switzerland, 1217
Actively Recruiting
6
Schmerzklinik Zürich AG
Zurich, Switzerland, 8050
Actively Recruiting
Research Team
L
Lidia Anguiano, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here